News Image

Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress

Provided By GlobeNewswire

Last update: Apr 9, 2025

– Clinical and preclinical data supporting dosing profile and tolerability for ABI-5366, a novel long-acting helicase-primase inhibitor candidate, featured in two poster presentations –

Read more at globenewswire.com

ASSEMBLY BIOSCIENCES INC

NASDAQ:ASMB (5/30/2025, 8:00:01 PM)

14.15

-0.05 (-0.35%)



Find more stocks in the Stock Screener

Follow ChartMill for more